Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;14(4):864-867.
doi: 10.21037/tau-2024-747. Epub 2025 Apr 15.

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Bryan J Neth  1 , Jeffrey S Wefel  2   3 , Kevin T Nead  3   4
Affiliations
Editorial

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Bryan J Neth et al. Transl Androl Urol. .
No abstract available

Keywords: Prostate cancer; cognitive; second-generation androgen receptor antagonists; toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-747/coif). J.S.W. reports grants from Bayer, GT Medical Technologies, and Novocure; consulting fees from Intra-Cellular Therapies; and participation on a Data Safety Monitoring Board or Advisory Board for Bayer. K.T.N. is a CPRIT Scholar in Cancer Research. The other author has no conflicts of interest to declare.

Comment on

References

    1. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. Endocr Rev 2021;42:354-73. 10.1210/endrev/bnab002 - DOI - PMC - PubMed
    1. Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21:1067-96. 10.6004/jnccn.2023.0050 - DOI - PubMed
    1. Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med 2018;8:a030635. 10.1101/cshperspect.a030635 - DOI - PMC - PubMed
    1. Chen Y, Zhou Q, Hankey W, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis 2022;13:632. 10.1038/s41419-022-05084-1 - DOI - PMC - PubMed
    1. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019;380:1235-46. 10.1056/NEJMoa1815671 - DOI - PubMed

LinkOut - more resources